PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study
Recruiting now · Phase 2
Conditions studied: Premenopausal HR+/HER2- Metastatic Breast Cancer
In brief
This study is a prospective, two-arm, randomized phase II study of talazoparib versus talazoparib plus atezolizumab in ER+ premeonopausal women with metastatic breast cancer harboring HRD scar 1st line treatment: GnRH agonist + Aromatase Inhibitor(AI) + Palbociclib 28 days after the last treatment of 1st line treatment(., randomization for 2nd line treatment is conducte to arm A(Talazoparib+Atezolizumab) and arm B(Talazoparib monotherapy)
Key facts
- Study ID
- NCT04819243
- Run by
- Samsung Medical Center
- People needed
- 178
- Starts
- 2021-08-25
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2025-01-03
Who can join
Age: 19 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Samsung medical Center — Seoul, Gannam-gu, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.